Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 47168.55 
• Atom Count: 2951 
• Residue Count: 410 
• Unique protein chains: 1

4ZUD

Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A resolution.

• DOI: 10.2210/pdb4ZUD/pdb

• Classification: MEMBRANE PROTEIN
• Organism(s): Escherichia coli, Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): 3 


• Deposited: 2015-05-15 Released: 2015-10-07 
• Deposition Author(s): Zhang, H., Unal, H., Desnoyer, R., Han, G.W., Patel, N., Katritch, V., Karnik, S.S., Cherezov, V., Stevens, R.C., GPCR Network (GPCR)
• Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences 

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.8 Å
• R-Value Free: 0.234 
• R-Value Work: 0.194 

Literature

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Zhang, H., Unal, H., Desnoyer, R., Han, G.W., Patel, N., Katritch, V., Karnik, S.S., Cherezov, V., Stevens, R.C.

(2015) J.Biol.Chem. 290: 29127-29139

• PubMed: 26420482 
• DOI: 10.1074/jbc.M115.689000


• PubMed Abstract: 
  

Angiotensin II type 1 receptor (AT1R) is the primary blood pressure regulator. AT1R blockers (ARBs) have been widely used in clinical settings as anti-hypertensive drugs and share a similar chemical scaffold, although even minor variations can lead to distinct therapeutic efficacies toward cardiovascular etiologies. The structural basis for AT1R modulation by different peptide and non-peptide ligands has remained elusive. Here, we report the crystal structure of the human AT1R in complex with an inverse agonist olmesartan (Benicar(TM)), a highly potent anti-hypertensive drug. Olmesartan is anchored to the receptor primarily by the residues Tyr-35(1.39), Trp-84(2.60), and Arg-167(ECL2), similar to the antagonist ZD7155, corroborating a common binding mode of different ARBs. Using docking simulations and site-directed mutagenesis, we identified specific interactions between AT1R and different ARBs, including olmesartan derivatives with inverse agonist, neutral antagonist, or agonist activities. We further observed that the mutation N111(3.35)A in the putative sodium-binding site affects binding of the endogenous peptide agonist angiotensin II but not the β-arrestin-biased peptide TRV120027.

---

Organizational Affiliation: 

From the Departments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089 and.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Chimera protein of Soluble cytochrome b562 and Type-1 angiotensin II receptor	A	410	Escherichia coli, Homo sapiens This entity is chimeric	Mutation(s): 3  Gene Names: cybC, AGTR1 (AGTR1A, AGTR1B, AT2R1, AT2R1B)
Membrane protein mpstruct	Group:  TRANSMEMBRANE PROTEINS: ALPHA-HELICAL		Sub Group:  G Protein-Coupled Receptors (GPCRs)	Protein:  Angiotensin type I receptor
Find proteins for P0ABE7 (Escherichia coli) Go to UniProtKB:  P0ABE7
Find proteins for P30556 (Homo sapiens) Go to Gene View: AGTR1 Go to UniProtKB:  P30556

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
OLM	A	Olmesartan C24 H26 N6 O3 VTRAEEWXHOVJFV-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
OLM	IC50: 7.7 - 8.1 nM (92) BINDINGDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.8 Å
• R-Value Free: 0.234 
• R-Value Work: 0.194 
• Space Group: P 3₂

Unit Cell:

Length (Å)	Angle (°)
a = 41.200	α = 90.00
b = 41.200	β = 90.00
c = 251.160	γ = 120.00

Software Package:

Software Name	Purpose
XDS	data reduction
XSCALE	data scaling
PHASER	phasing
REFMAC	refinement

Structure Validation

Entry History & Funding Information

Deposition Data

• Deposited Date: 2015-05-15 
• Released Date: 2015-10-07 
• Deposition Author(s): Zhang, H., Unal, H., Desnoyer, R., Han, G.W., Patel, N., Katritch, V., Karnik, S.S., Cherezov, V., Stevens, R.C., GPCR Network (GPCR)

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Institute of General Medical Sciences	United States	U54 GM094618

Revision History 

• Version 1.0: 2015-10-07
  Type: Initial release
• Version 1.1: 2015-10-14
  Type: Database references
• Version 1.2: 2015-12-16
  Type: Database references
• Version 1.3: 2017-09-20
  Type: Author supporting evidence, Database references, Derived calculations